菜单

Perspectives

Advancing Microbial Fermentation for Innovative Biologics
May. 19, 2026
Advancing Microbial Fermentation for Innovative Biologics

Microbial fermentation is powering a growing range of innovative biologics—such as enzymes, cytokines, growth hormones, nanobodies, and virus-like particles—but development can be hindered by genetic/expression instability, leaky expression, toxic by-products, unwanted PTMs, inclusion bodies, and scale-up uncertainty that can erode yield and quality.

 

In this American Pharmaceutical Review feature, Sam Zhang (VP and Head of MVP, WuXi Biologics) outlines how modern strain engineering and process innovation can improve robustness across the workflow. The article highlights engineered E. coli strategies (e.g., improved plasmid stability without antibiotics, tighter repression to reduce leaky expression, mitigation of unwanted PTMs, and enhanced phage resistance), paired with DoE/PAT-driven modeling and high-throughput screening to optimize upstream performance. It also discusses downstream “toolbox” approaches (e.g., His‑SUMO tagging and optimized refolding) and robust scale-up models supported by flexible GMP infrastructure.

    
Read the full article: Advancing Microbial Fermentation for Innovative Biologics